Medpace Holdings, Inc. (MEDP) Stock Competitors & Peer Comparison
See (MEDP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEDP | $519.96 | +1.40% | 14.8B | 32.68 | $15.91 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $505.75 | +2.75% | 187.9B | 21.84 | $23.16 | +0.36% |
| DHR | $193.21 | +2.30% | 136.8B | 24.21 | $7.98 | +0.70% |
| IDXX | $554.94 | +1.05% | 43.8B | 40.86 | $13.58 | N/A |
| A | $135.51 | +2.95% | 38.3B | 23.32 | $5.81 | +0.74% |
| NTRA | $260.74 | +0.30% | 37.3B | -163.99 | -$1.59 | N/A |
| IQV | $186.43 | +0.44% | 31.1B | 15.37 | $12.13 | N/A |
| ILMN | $177.65 | +1.46% | 26.9B | 35.32 | $5.03 | N/A |
| MTD | $1,243.42 | +3.34% | 25.1B | 28.58 | $43.51 | N/A |
Stock Comparison
MEDP vs DHR-PB Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, MEDP is priced at $519.96, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, MEDP's ROE is +1.21%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, MEDP is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check DHR-PB's competition here
MEDP vs TMO Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, TMO has a market cap of 187.9B. Regarding current trading prices, MEDP is priced at $519.96, while TMO trades at $505.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas TMO's P/E ratio is 21.84. In terms of profitability, MEDP's ROE is +1.21%, compared to TMO's ROE of +0.13%. Regarding short-term risk, MEDP is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check TMO's competition here
MEDP vs DHR Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, DHR has a market cap of 136.8B. Regarding current trading prices, MEDP is priced at $519.96, while DHR trades at $193.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas DHR's P/E ratio is 24.21. In terms of profitability, MEDP's ROE is +1.21%, compared to DHR's ROE of +0.07%. Regarding short-term risk, MEDP is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check DHR's competition here
MEDP vs IDXX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, IDXX has a market cap of 43.8B. Regarding current trading prices, MEDP is priced at $519.96, while IDXX trades at $554.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas IDXX's P/E ratio is 40.86. In terms of profitability, MEDP's ROE is +1.21%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, MEDP is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check IDXX's competition here
MEDP vs A Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, A has a market cap of 38.3B. Regarding current trading prices, MEDP is priced at $519.96, while A trades at $135.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas A's P/E ratio is 23.32. In terms of profitability, MEDP's ROE is +1.21%, compared to A's ROE of +0.21%. Regarding short-term risk, MEDP is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check A's competition here
MEDP vs NTRA Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NTRA has a market cap of 37.3B. Regarding current trading prices, MEDP is priced at $519.96, while NTRA trades at $260.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NTRA's P/E ratio is -163.99. In terms of profitability, MEDP's ROE is +1.21%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, MEDP is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NTRA's competition here
MEDP vs IQV Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, IQV has a market cap of 31.1B. Regarding current trading prices, MEDP is priced at $519.96, while IQV trades at $186.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas IQV's P/E ratio is 15.37. In terms of profitability, MEDP's ROE is +1.21%, compared to IQV's ROE of +0.22%. Regarding short-term risk, MEDP is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check IQV's competition here
MEDP vs ILMN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ILMN has a market cap of 26.9B. Regarding current trading prices, MEDP is priced at $519.96, while ILMN trades at $177.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ILMN's P/E ratio is 35.32. In terms of profitability, MEDP's ROE is +1.21%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, MEDP is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check ILMN's competition here
MEDP vs MTD Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, MTD has a market cap of 25.1B. Regarding current trading prices, MEDP is priced at $519.96, while MTD trades at $1,243.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas MTD's P/E ratio is 28.58. In terms of profitability, MEDP's ROE is +1.21%, compared to MTD's ROE of -6.10%. Regarding short-term risk, MEDP is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check MTD's competition here
MEDP vs WAT Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, MEDP is priced at $519.96, while WAT trades at $376.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas WAT's P/E ratio is 27.75. In terms of profitability, MEDP's ROE is +1.21%, compared to WAT's ROE of +0.08%. Regarding short-term risk, MEDP is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check WAT's competition here
MEDP vs DGX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, DGX has a market cap of 22.9B. Regarding current trading prices, MEDP is priced at $519.96, while DGX trades at $206.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas DGX's P/E ratio is 20.37. In terms of profitability, MEDP's ROE is +1.21%, compared to DGX's ROE of +0.14%. Regarding short-term risk, MEDP is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check DGX's competition here
MEDP vs LH Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, LH has a market cap of 21.8B. Regarding current trading prices, MEDP is priced at $519.96, while LH trades at $266.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas LH's P/E ratio is 15.80. In terms of profitability, MEDP's ROE is +1.21%, compared to LH's ROE of +0.11%. Regarding short-term risk, MEDP is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check LH's competition here
MEDP vs EXAS Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, MEDP is priced at $519.96, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas EXAS's P/E ratio is -95.37. In terms of profitability, MEDP's ROE is +1.21%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, MEDP is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check EXAS's competition here
MEDP vs GH Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, GH has a market cap of 19B. Regarding current trading prices, MEDP is priced at $519.96, while GH trades at $142.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas GH's P/E ratio is -55.40. In terms of profitability, MEDP's ROE is +1.21%, compared to GH's ROE of +1.84%. Regarding short-term risk, MEDP is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check GH's competition here
MEDP vs ILMNV Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, MEDP is priced at $519.96, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ILMNV's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to ILMNV's ROE of N/A. Regarding short-term risk, MEDP is more volatile compared to ILMNV. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check ILMNV's competition here
MEDP vs PKI Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, MEDP is priced at $519.96, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PKI's P/E ratio is 41.45. In terms of profitability, MEDP's ROE is +1.21%, compared to PKI's ROE of +0.03%. Regarding short-term risk, MEDP is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check PKI's competition here
MEDP vs RVTY Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, RVTY has a market cap of 12.7B. Regarding current trading prices, MEDP is priced at $519.96, while RVTY trades at $113.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas RVTY's P/E ratio is 22.17. In terms of profitability, MEDP's ROE is +1.21%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, MEDP is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check RVTY's competition here
MEDP vs ICLR Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ICLR has a market cap of 12.3B. Regarding current trading prices, MEDP is priced at $519.96, while ICLR trades at $160.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ICLR's P/E ratio is 13.13. In terms of profitability, MEDP's ROE is +1.21%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, MEDP is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check ICLR's competition here
MEDP vs CRL Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CRL has a market cap of 10.2B. Regarding current trading prices, MEDP is priced at $519.96, while CRL trades at $212.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CRL's P/E ratio is 21.27. In terms of profitability, MEDP's ROE is +1.21%, compared to CRL's ROE of -0.06%. Regarding short-term risk, MEDP is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check CRL's competition here
MEDP vs QGEN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, QGEN has a market cap of 8B. Regarding current trading prices, MEDP is priced at $519.96, while QGEN trades at $38.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas QGEN's P/E ratio is 16.23. In terms of profitability, MEDP's ROE is +1.21%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, MEDP is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check QGEN's competition here
MEDP vs TWST Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, TWST has a market cap of 6B. Regarding current trading prices, MEDP is priced at $519.96, while TWST trades at $96.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas TWST's P/E ratio is -47.38. In terms of profitability, MEDP's ROE is +1.21%, compared to TWST's ROE of -0.17%. Regarding short-term risk, MEDP is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check TWST's competition here
MEDP vs BLLN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BLLN has a market cap of 5.2B. Regarding current trading prices, MEDP is priced at $519.96, while BLLN trades at $112.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BLLN's P/E ratio is 204.07. In terms of profitability, MEDP's ROE is +1.21%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, MEDP is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BLLN's competition here
MEDP vs SHC Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, SHC has a market cap of 4.9B. Regarding current trading prices, MEDP is priced at $519.96, while SHC trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas SHC's P/E ratio is 19.00. In terms of profitability, MEDP's ROE is +1.21%, compared to SHC's ROE of +0.21%. Regarding short-term risk, MEDP is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check SHC's competition here
MEDP vs RDNT Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, RDNT has a market cap of 4.7B. Regarding current trading prices, MEDP is priced at $519.96, while RDNT trades at $60.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas RDNT's P/E ratio is 130.46. In terms of profitability, MEDP's ROE is +1.21%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, MEDP is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check RDNT's competition here
MEDP vs SYNH Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, MEDP is priced at $519.96, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas SYNH's P/E ratio is 61.40. In terms of profitability, MEDP's ROE is +1.21%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, MEDP is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check SYNH's competition here
MEDP vs OLK Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, MEDP is priced at $519.96, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas OLK's P/E ratio is -96.59. In terms of profitability, MEDP's ROE is +1.21%, compared to OLK's ROE of -0.07%. Regarding short-term risk, MEDP is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check OLK's competition here
MEDP vs GRAL Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, GRAL has a market cap of 2.9B. Regarding current trading prices, MEDP is priced at $519.96, while GRAL trades at $66.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas GRAL's P/E ratio is -6.42. In terms of profitability, MEDP's ROE is +1.21%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, MEDP is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check GRAL's competition here
MEDP vs NEOG Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NEOG has a market cap of 2.1B. Regarding current trading prices, MEDP is priced at $519.96, while NEOG trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NEOG's P/E ratio is 33.96. In terms of profitability, MEDP's ROE is +1.21%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, MEDP is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NEOG's competition here
MEDP vs CDNA Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CDNA has a market cap of 1.4B. Regarding current trading prices, MEDP is priced at $519.96, while CDNA trades at $27.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CDNA's P/E ratio is 33.15. In terms of profitability, MEDP's ROE is +1.21%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, MEDP is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check CDNA's competition here
MEDP vs PSNL Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PSNL has a market cap of 1.1B. Regarding current trading prices, MEDP is priced at $519.96, while PSNL trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PSNL's P/E ratio is -12.34. In terms of profitability, MEDP's ROE is +1.21%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, MEDP is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check PSNL's competition here
MEDP vs CSTL Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CSTL has a market cap of 694.9M. Regarding current trading prices, MEDP is priced at $519.96, while CSTL trades at $22.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CSTL's P/E ratio is -52.07. In terms of profitability, MEDP's ROE is +1.21%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, MEDP is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check CSTL's competition here
MEDP vs GRALV Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, MEDP is priced at $519.96, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas GRALV's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to GRALV's ROE of N/A. Regarding short-term risk, MEDP is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check GRALV's competition here
MEDP vs FLGT Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, FLGT has a market cap of 552.1M. Regarding current trading prices, MEDP is priced at $519.96, while FLGT trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas FLGT's P/E ratio is 1944.00. In terms of profitability, MEDP's ROE is +1.21%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, MEDP is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check FLGT's competition here
MEDP vs MYGN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, MYGN has a market cap of 512.9M. Regarding current trading prices, MEDP is priced at $519.96, while MYGN trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas MYGN's P/E ratio is -41.77. In terms of profitability, MEDP's ROE is +1.21%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, MEDP is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check MYGN's competition here
MEDP vs CO Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, MEDP is priced at $519.96, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CO's P/E ratio is 5.06. In terms of profitability, MEDP's ROE is +1.21%, compared to CO's ROE of +0.11%. Regarding short-term risk, MEDP is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check CO's competition here
MEDP vs NEO Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NEO has a market cap of 357.6M. Regarding current trading prices, MEDP is priced at $519.96, while NEO trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NEO's P/E ratio is 105.62. In terms of profitability, MEDP's ROE is +1.21%, compared to NEO's ROE of -0.12%. Regarding short-term risk, MEDP is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NEO's competition here
MEDP vs PRE Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PRE has a market cap of 335.8M. Regarding current trading prices, MEDP is priced at $519.96, while PRE trades at $19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PRE's P/E ratio is -9.59. In terms of profitability, MEDP's ROE is +1.21%, compared to PRE's ROE of -0.47%. Regarding short-term risk, MEDP is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check PRE's competition here
MEDP vs FLDM Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, MEDP is priced at $519.96, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas FLDM's P/E ratio is -4.74. In terms of profitability, MEDP's ROE is +1.21%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, MEDP is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check FLDM's competition here
MEDP vs BDSX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BDSX has a market cap of 163.1M. Regarding current trading prices, MEDP is priced at $519.96, while BDSX trades at $20.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BDSX's P/E ratio is -4.94. In terms of profitability, MEDP's ROE is +1.21%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, MEDP is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BDSX's competition here
MEDP vs IMDX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, IMDX has a market cap of 150M. Regarding current trading prices, MEDP is priced at $519.96, while IMDX trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas IMDX's P/E ratio is -4.70. In terms of profitability, MEDP's ROE is +1.21%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, MEDP is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check IMDX's competition here
MEDP vs GTH Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, MEDP is priced at $519.96, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas GTH's P/E ratio is -1.11. In terms of profitability, MEDP's ROE is +1.21%, compared to GTH's ROE of -1.01%. Regarding short-term risk, MEDP is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check GTH's competition here
MEDP vs XGN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, XGN has a market cap of 112.1M. Regarding current trading prices, MEDP is priced at $519.96, while XGN trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas XGN's P/E ratio is -6.27. In terms of profitability, MEDP's ROE is +1.21%, compared to XGN's ROE of -1.14%. Regarding short-term risk, MEDP is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check XGN's competition here
MEDP vs GENE Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, MEDP is priced at $519.96, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas GENE's P/E ratio is -38.25. In terms of profitability, MEDP's ROE is +1.21%, compared to GENE's ROE of -1.85%. Regarding short-term risk, MEDP is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check GENE's competition here
MEDP vs STIM Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, STIM has a market cap of 88.4M. Regarding current trading prices, MEDP is priced at $519.96, while STIM trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas STIM's P/E ratio is -2.35. In terms of profitability, MEDP's ROE is +1.21%, compared to STIM's ROE of -1.65%. Regarding short-term risk, MEDP is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check STIM's competition here
MEDP vs ATLN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ATLN has a market cap of 79.3M. Regarding current trading prices, MEDP is priced at $519.96, while ATLN trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ATLN's P/E ratio is -0.78. In terms of profitability, MEDP's ROE is +1.21%, compared to ATLN's ROE of +38.02%. Regarding short-term risk, MEDP is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check ATLN's competition here
MEDP vs SERA Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, SERA has a market cap of 68.7M. Regarding current trading prices, MEDP is priced at $519.96, while SERA trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas SERA's P/E ratio is -2.77. In terms of profitability, MEDP's ROE is +1.21%, compared to SERA's ROE of -0.41%. Regarding short-term risk, MEDP is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check SERA's competition here
MEDP vs DRIO Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, DRIO has a market cap of 45M. Regarding current trading prices, MEDP is priced at $519.96, while DRIO trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas DRIO's P/E ratio is -1.05. In terms of profitability, MEDP's ROE is +1.21%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, MEDP is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check DRIO's competition here
MEDP vs STRR Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, STRR has a market cap of 40.4M. Regarding current trading prices, MEDP is priced at $519.96, while STRR trades at $10.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas STRR's P/E ratio is -11.51. In terms of profitability, MEDP's ROE is +1.21%, compared to STRR's ROE of -0.14%. Regarding short-term risk, MEDP is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check STRR's competition here
MEDP vs STRRP Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, STRRP has a market cap of 40.3M. Regarding current trading prices, MEDP is priced at $519.96, while STRRP trades at $9.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas STRRP's P/E ratio is -17.89. In terms of profitability, MEDP's ROE is +1.21%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, MEDP is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check STRRP's competition here
MEDP vs PRPO Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PRPO has a market cap of 40M. Regarding current trading prices, MEDP is priced at $519.96, while PRPO trades at $22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PRPO's P/E ratio is -16.00. In terms of profitability, MEDP's ROE is +1.21%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, MEDP is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check PRPO's competition here
MEDP vs AKU Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, MEDP is priced at $519.96, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas AKU's P/E ratio is -0.13. In terms of profitability, MEDP's ROE is +1.21%, compared to AKU's ROE of -5.32%. Regarding short-term risk, MEDP is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check AKU's competition here
MEDP vs MDXH Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, MDXH has a market cap of 23.4M. Regarding current trading prices, MEDP is priced at $519.96, while MDXH trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas MDXH's P/E ratio is -1.20. In terms of profitability, MEDP's ROE is +1.21%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, MEDP is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check MDXH's competition here
MEDP vs QUCY Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, QUCY has a market cap of 18.4M. Regarding current trading prices, MEDP is priced at $519.96, while QUCY trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas QUCY's P/E ratio is -0.07. In terms of profitability, MEDP's ROE is +1.21%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, MEDP is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check QUCY's competition here
MEDP vs CEMI Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, MEDP is priced at $519.96, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CEMI's P/E ratio is -0.63. In terms of profitability, MEDP's ROE is +1.21%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, MEDP is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check CEMI's competition here
MEDP vs ENZ Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, MEDP is priced at $519.96, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ENZ's P/E ratio is -2.24. In terms of profitability, MEDP's ROE is +1.21%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, MEDP is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check ENZ's competition here
MEDP vs PMD Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, MEDP is priced at $519.96, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PMD's P/E ratio is -5.24. In terms of profitability, MEDP's ROE is +1.21%, compared to PMD's ROE of -0.32%. Regarding short-term risk, MEDP is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check PMD's competition here
MEDP vs ME Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, MEDP is priced at $519.96, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ME's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.21%, compared to ME's ROE of -7.71%. Regarding short-term risk, MEDP is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check ME's competition here
MEDP vs MYNZ Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, MEDP is priced at $519.96, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, MEDP's ROE is +1.21%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, MEDP is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check MYNZ's competition here
MEDP vs BNGO Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BNGO has a market cap of 12.9M. Regarding current trading prices, MEDP is priced at $519.96, while BNGO trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BNGO's P/E ratio is -0.26. In terms of profitability, MEDP's ROE is +1.21%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, MEDP is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check BNGO's competition here
MEDP vs CHEK Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, MEDP is priced at $519.96, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CHEK's P/E ratio is -0.43. In terms of profitability, MEDP's ROE is +1.21%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, MEDP is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check CHEK's competition here
MEDP vs CNTG Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, MEDP is priced at $519.96, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CNTG's P/E ratio is -0.23. In terms of profitability, MEDP's ROE is +1.21%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, MEDP is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check CNTG's competition here
MEDP vs BNR Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BNR has a market cap of 8.2M. Regarding current trading prices, MEDP is priced at $519.96, while BNR trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BNR's P/E ratio is -9.51. In terms of profitability, MEDP's ROE is +1.21%, compared to BNR's ROE of -0.11%. Regarding short-term risk, MEDP is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BNR's competition here
MEDP vs VNRX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, VNRX has a market cap of 7.6M. Regarding current trading prices, MEDP is priced at $519.96, while VNRX trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas VNRX's P/E ratio is -0.61. In terms of profitability, MEDP's ROE is +1.21%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, MEDP is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check VNRX's competition here
MEDP vs APDN Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, MEDP is priced at $519.96, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas APDN's P/E ratio is -0.10. In terms of profitability, MEDP's ROE is +1.21%, compared to APDN's ROE of -6.53%. Regarding short-term risk, MEDP is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check APDN's competition here
MEDP vs MBAI Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, MBAI has a market cap of 6.5M. Regarding current trading prices, MEDP is priced at $519.96, while MBAI trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas MBAI's P/E ratio is 1.66. In terms of profitability, MEDP's ROE is +1.21%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, MEDP is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check MBAI's competition here
MEDP vs NVTA Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, MEDP is priced at $519.96, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NVTA's P/E ratio is -0.00. In terms of profitability, MEDP's ROE is +1.21%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, MEDP is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NVTA's competition here
MEDP vs ADVB Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ADVB has a market cap of 5.4M. Regarding current trading prices, MEDP is priced at $519.96, while ADVB trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ADVB's P/E ratio is -45.36. In terms of profitability, MEDP's ROE is +1.21%, compared to ADVB's ROE of -0.65%. Regarding short-term risk, MEDP is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check ADVB's competition here
MEDP vs LMDX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, MEDP is priced at $519.96, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas LMDX's P/E ratio is -0.01. In terms of profitability, MEDP's ROE is +1.21%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, MEDP is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check LMDX's competition here
MEDP vs LMDXW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, MEDP is priced at $519.96, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, MEDP's ROE is +1.21%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, MEDP is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check LMDXW's competition here
MEDP vs BIAFW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BIAFW has a market cap of 5M. Regarding current trading prices, MEDP is priced at $519.96, while BIAFW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BIAFW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, MEDP is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check BIAFW's competition here
MEDP vs BGLC Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BGLC has a market cap of 4.1M. Regarding current trading prices, MEDP is priced at $519.96, while BGLC trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BGLC's P/E ratio is -1.37. In terms of profitability, MEDP's ROE is +1.21%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, MEDP is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BGLC's competition here
MEDP vs BIAF Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BIAF has a market cap of 3.8M. Regarding current trading prices, MEDP is priced at $519.96, while BIAF trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BIAF's P/E ratio is -0.10. In terms of profitability, MEDP's ROE is +1.21%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, MEDP is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BIAF's competition here
MEDP vs TRIB Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, TRIB has a market cap of 3.6M. Regarding current trading prices, MEDP is priced at $519.96, while TRIB trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas TRIB's P/E ratio is -0.14. In terms of profitability, MEDP's ROE is +1.21%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, MEDP is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check TRIB's competition here
MEDP vs DMTK Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, MEDP is priced at $519.96, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas DMTK's P/E ratio is -0.04. In terms of profitability, MEDP's ROE is +1.21%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, MEDP is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check DMTK's competition here
MEDP vs NDRA Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NDRA has a market cap of 3.2M. Regarding current trading prices, MEDP is priced at $519.96, while NDRA trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NDRA's P/E ratio is -0.55. In terms of profitability, MEDP's ROE is +1.21%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, MEDP is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NDRA's competition here
MEDP vs NOTV Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, MEDP is priced at $519.96, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NOTV's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.21%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, MEDP is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NOTV's competition here
MEDP vs SQL Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, MEDP is priced at $519.96, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas SQL's P/E ratio is -0.40. In terms of profitability, MEDP's ROE is +1.21%, compared to SQL's ROE of +38.02%. Regarding short-term risk, MEDP is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check SQL's competition here
MEDP vs AWH Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, MEDP is priced at $519.96, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas AWH's P/E ratio is -0.09. In terms of profitability, MEDP's ROE is +1.21%, compared to AWH's ROE of +2.03%. Regarding short-term risk, MEDP is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check AWH's competition here
MEDP vs INBS Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, INBS has a market cap of 1.4M. Regarding current trading prices, MEDP is priced at $519.96, while INBS trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas INBS's P/E ratio is -0.25. In terms of profitability, MEDP's ROE is +1.21%, compared to INBS's ROE of -1.74%. Regarding short-term risk, MEDP is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check INBS's competition here
MEDP vs HTGM Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, MEDP is priced at $519.96, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas HTGM's P/E ratio is -0.03. In terms of profitability, MEDP's ROE is +1.21%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, MEDP is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check HTGM's competition here
MEDP vs BIOC Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, MEDP is priced at $519.96, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BIOC's P/E ratio is -0.01. In terms of profitability, MEDP's ROE is +1.21%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, MEDP is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BIOC's competition here
MEDP vs ISPC Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, ISPC has a market cap of 351.3K. Regarding current trading prices, MEDP is priced at $519.96, while ISPC trades at $2.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas ISPC's P/E ratio is -0.08. In terms of profitability, MEDP's ROE is +1.21%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, MEDP is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check ISPC's competition here
MEDP vs PRENW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PRENW has a market cap of 195.6K. Regarding current trading prices, MEDP is priced at $519.96, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PRENW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, MEDP is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check PRENW's competition here
MEDP vs SQLLW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, MEDP is priced at $519.96, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, MEDP's ROE is +1.21%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, MEDP is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check SQLLW's competition here
MEDP vs DHR-PA Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, MEDP's ROE is +1.21%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, MEDP is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check DHR-PA's competition here
MEDP vs OCDX Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas OCDX's P/E ratio is -42.28. In terms of profitability, MEDP's ROE is +1.21%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, MEDP is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check OCDX's competition here
MEDP vs BNGOW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas BNGOW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, MEDP is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check BNGOW's competition here
MEDP vs PRXL Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas PRXL's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, MEDP is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for MEDP.Check PRXL's competition here
MEDP vs MEUSW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas MEUSW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, MEDP is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check MEUSW's competition here
MEDP vs NDRAW Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas NDRAW's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, MEDP is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check NDRAW's competition here
MEDP vs CHEKZ Comparison June 2026
MEDP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEDP stands at 14.8B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, MEDP is priced at $519.96, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEDP currently has a P/E ratio of 32.68, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, MEDP's ROE is +1.21%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, MEDP is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for MEDP.Check CHEKZ's competition here